Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hy... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More
U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787338) titled 'SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Posit... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy ... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2 arm parallel-group, double-blind, placebo... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'Bepirovirsen Liver Biopsy study'. The following are the other relevant details related to the tria... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxe... Read More
U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07788079) titled 'The Effect of Ostomy Care Education Applied With the Teach-Back Method to Ostomy-Opened Ind... Read More
Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxe... Read More